{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:06:27Z","timestamp":1783519587950,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004189","name":"Max-Planck-Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbrc.2020.11.117","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T16:42:16Z","timestamp":1607618536000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs"],"prefix":"10.1016","volume":"534","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-8607","authenticated-orcid":false,"given":"Christopher","family":"Heim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-2748","authenticated-orcid":false,"given":"Samuel","family":"Maiwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steinebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Strope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"G\u00fctschow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-5677","authenticated-orcid":false,"given":"Marcus D.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.11.117_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2020.11.117_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CCO.0b013e32833d752c","article-title":"Recent advances of IMiDs in cancer therapy","volume":"22","author":"Li","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00007691-200202000-00017","article-title":"5\u2019-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis","volume":"24","author":"Price","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbrc.2020.11.117_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0968-0896(00)00323-0","article-title":"Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in\u00a0vitro","volume":"9","author":"Gutschow","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib5","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1021\/jm020079d","article-title":"Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine","volume":"46","author":"Luzzio","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182152","article-title":"Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others","volume":"12","author":"Tokunaga","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.11.117_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cmdc.201600629","article-title":"Old drug scaffold, new activity: thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression","volume":"12","author":"Iacopetta","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2020.11.117_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biom9090446","article-title":"New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities","volume":"9","author":"Cieslak","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2020.11.117_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900376","article-title":"Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction","volume":"353","author":"Xiao","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bbrc.2020.11.117_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bmc.2003.11.007","article-title":"Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer","volume":"12","author":"Capitosti","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1021\/jm0304820","article-title":"Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors","volume":"47","author":"Lepper","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib12","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/cmdc.201800263","article-title":"Synthesis, structural characterization, and antiangiogenic activity of polyfluorinated benzamides","volume":"13","author":"Steinebach","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2020.11.117_bib13","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1158\/1535-7163.MCT-15-0320","article-title":"Anticancer properties of a novel class of tetrafluorinated thalidomide analogues","volume":"14","author":"Beedie","year":"2015","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2020.11.117_bib14","first-page":"3189","article-title":"Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues","volume":"63","author":"Ng","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.11.117_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.11.117_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.11.117_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.11.117_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.11.117_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.11.117_bib20","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1021\/acsomega.8b00959","article-title":"Chemical ligand space of cereblon","volume":"3","author":"Boichenko","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2020.11.117_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128342","article-title":"Structural dynamics of the cereblon ligand binding domain","volume":"10","author":"Hartmann","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.11.117_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jsb.2014.10.010","article-title":"Thalidomide mimics uridine binding to an aromatic cage in cereblon","volume":"188","author":"Hartmann","year":"2014","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib24","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the chemical knockdown of cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib25","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1039\/C8CC09541H","article-title":"PROTAC-mediated crosstalk between E3 ligases","volume":"55","author":"Steinebach","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbrc.2020.11.117_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bbrc.2020.11.117_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ddtec.2019.02.002","article-title":"A\u00a0critical evaluation of the approaches to targeted protein degradation for drug discovery","volume":"31","author":"Chopra","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cbpa.2019.07.003","article-title":"Bifunctional chemical probes inducing protein-protein interactions","volume":"52","author":"Maniaci","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bbrc.2020.11.117_bib31","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201903060RR","article-title":"Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs","author":"Beedie","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.bbrc.2020.11.117_bib32","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1021\/acs.jmedchem.9b00454","article-title":"De-novo design of cereblon (CRBN) effectors guided by natural hydrolysis products of thalidomide derivatives","volume":"62","author":"Heim","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cmdc.201600496","article-title":"Synthesis and antiangiogenic properties of tetrafluorophthalimido and tetrafluorobenzamido barbituric acids","volume":"11","author":"Ambrozak","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2020.11.117_bib34","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1039\/D0SC00167H","article-title":"Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders","volume":"11","author":"Steinebach","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bbrc.2020.11.117_bib35","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/cmdc.201800271","article-title":"Efficient synthesis of immunomodulatory drug analogues enables exploration of structure-degradation relationships","volume":"13","author":"Burslem","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2020.11.117_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0014-827X(01)01131-4","article-title":"Synthesis, spectroscopic characterization, stability assessment and DNA-binding of new 2,6-piperidinedione derivatives","volume":"56","author":"Abou-Zeid","year":"2001","journal-title":"Farmaco"},{"key":"10.1016\/j.bbrc.2020.11.117_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jmedchem.5b01735","article-title":"A\u00a0FRET-based assay for the identification and characterization of cereblon ligands","volume":"59","author":"Boichenko","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2020.11.117_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.intimp.2014.05.007","article-title":"In\u00a0vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs","volume":"21","author":"El-Aarag","year":"2014","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.bbrc.2020.11.117_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.bbrc.2020.11.117_bib40","article-title":"Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay","author":"Maiwald","year":"2020","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20321616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20321616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:58:12Z","timestamp":1757764692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20321616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"alternative-id":["S0006291X20321616"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.117","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}